Skip to main content

Advertisement

ADVERTISEMENT

CIO2022 Highlights

Ghassan Abou-Alfa, MD, MBA Discusses the EMERALD-3 Trial

Ghassan Abou-Alfa, MD, MBA; Attending, Memorial Sloan Kettering Cancer Center; Professor, Weill Cornell College at Cornell University

Introduction

Dr Abou-Alfa discusses his CIO2022 abstract, "Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3."

CLICK HERE TO READ THE FULL ABSTRACT AND VIEW POSTER

Video

Advertisement

Advertisement

Advertisement